Discover more from C’s Newsletter
The Duality of Steve Kirsch - Remdesivir and Vaccine Adverse Events.
“Marine, what is that button on your body armor?”
“A Remdesivir button, sir.”
“Where’d you get it?”
“I don’t remember sir.”
“What is that you’ve got written on your helmet?”
“Vaccine Adverse Events, sir.”
“You write Vaccine Adverse Events on your helmet, and you wear a Remdesivir button. What’s that supposed to be, some kind of sick joke?”
“What is it supposed to mean?”
“I don’t know sir.”
“You don’t know very much do you?”
“You better get your head and your ass wired together or I will take a giant shit on you.”
“Answer my question or you’ll be standing tall before the man.”
“I think I was trying to suggest something about the duality of man sir.”
“The duality of man, the Jungian thing sir.”
“Who’s side are you on son?”
“Our side sir.”
“Don’t you love your country?”
“Well how about getting with the program. Why don’t you jump on the team and come on in for the big win?”
Steve Kirsch established Covid Early Treatment Fund (CETF) in April 2020.
According to its founder, serial tech entrepreneur Steve Kirsch, CETF was started in April 2020 in order to fund drug repurposing research to find the fastest and most cost-effective early outpatient treatments for COVID-19.
He let Rockefeller Philanthropy Advisors manage the fund.
COVID-19 Early Treatment Fund (CETF) was established by entrepreneur and philanthropist Steve Kirsch to fund outpatient clinical trials on re-purposed drugs, the quickest, safest, and lowest cost way to re-open our world until better drugs are discovered. CETF is managed by Rockefeller Philanthropy Advisors (RPA), a 501(c)(3) charity. The CETF Scientific Advisory Board (SAB) recommends the grants and RPA disburses the funds. The scientific advisory board includes Dr. Robert Siliciano, an immunologist and virologist Johns Hopkins University; Dr. Rich D’Aquila, an infectious disease expert at Northwestern University and Harvard clinical trials expert Dr. Raj Gandhi.
Continuing the Rockefeller family’s legacy of thoughtful, effective philanthropy, RPA is a global nonprofit that remains at the forefront of philanthropic growth and innovation, with a diverse team of experienced grantmakers with significant depth of knowledge across the spectrum of issue areas. Founded in 2002, RPA has grown into one of the world’s largest philanthropic service organizations and has facilitated more than $4 billion in grantmaking to more than 70 countries.
Kirsch’s CETF funded research on several chemical compounds, including Remdesivir.
Thus far, CETF has raised funding for clinical trials for drug candidates including Peginterferon lambda, a hepatitis D treatment, and Camostat mesylate, a protease inhibitor used to treat reflux esophagitis and chronic pancreatitis. The organization is also raising funds to support COVID-related trials of remdesivir, a broad-spectrum antiviral developed by Gilead Sciences, and Toyama Chemical's favipiravir, an antiviral medication currently used to treat influenza in Japan.
The CETF was reported to be in the process of raising funds for Peginterferon lambda trials at Stanford University.
CETF has raised partial funding for clinical trials of two of the top four drug candidates, Peginterferon lambda, a hepatitis D treatment, and Camostat mesylate, a protease inhibitor used to treat reflux esophagitis and chronic pancreatitis. The fund has awarded $100,000 so far to Aarhus University in Denmark to test Camostat mesylate, which may disrupt the ability of the virus to latch onto and enter lung cells, and is in the process of raising an additional $500,000 in support of clinical trials at Stanford University for Peginterferon lambda, which reactivates the body's virus-impacted interferon production response to fight the disease.
The Peginterferon lambda trials at Stanford used Remdesivir in the control/placebo group. (Almost anything will show a “benefit” when you compare it to the high death rates from Remdesivir. It is a form of statistical deception. Both the “test” and “control” groups can both be poisonous, but the less poisonous substance can be approved by the FDA. The poison Remdesivir had recently been granted an EUA by the FDA, making comparisons easy).
This is a phase 2, single-blinded, randomized trial of a single dose of Peginterferon Lambda-1a compared with placebo in outpatients with mild COVID-19. Study participants will be randomly assigned 1:1 to a single subcutaneous dose of Peginterferon Lambda-1a or placebo along with the standard of care.
Note again that the Stanford control group received placebo + standard of care. Stanford did not specifically report that Remdesivir was to be the standard of care, but they did note that Remdesivir had just been approved by the FDA, so it seems likely that Remdesivir was the standard of care.
Half of the participants will be randomly chosen to receive the study drug and the other half will receive the placebo. ... Remdesivir was just approved by the government (Food and Drug Administration) only for treatment of patients in the hospital and must be given by vein.
Stanford reported their results here: Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
There were 120 patients, 60 in each group.
Thus, there will be two arms: (1) the control arm, comprised of placebo in addition to standard supportive care and (2) the treatment arm, comprised of a single dose of peginterferon lamba-1a in addition to standard supportive care.
I’ve looked through Stanford’s data, and cannot find any statistics on the deaths in that study, if any. Standford published several tables but I don’t see their death statistics.
Mr. Kirsch is a very intelligent person with strong math skills. He’s funded important and informative research into the VAERS statistics. So I invite him to come on in for the big win and help us figure out what happened here.
The best way to prove criminal intent of Anthony Fauci and the rest of his co-conspirators is to highlight the high death rates associated with Remdesivir compared to Hydroxychloroquine in simultaneous government-funded studies.
Apparently Mr. Kirsch either does not agree with my assessment, or has some serious conflict of interest that he has not disclosed. As MIT Technology Review reported in October 2021:
A few months ago, Kirsch suddenly stopped promoting hydroxychloroquine—even scrubbing it from the CETF’s official list of trials it has funded. He wrote on his personal website that he’d been advised that being associated with the drug “would immediately trash my credibility.”
China posted a virus sequence on January 10, 2020. Whether that virus leaked, was intentionally released, was taken from a database and reproduced from that sequence, or if it ever existed in the way it was reported, doesn’t really matter. The response to China’s posting of the virus was where the Plandemic really kicked in. The US said, “oh, look, that’s a NOVEL coronavirus, therefore we can issue EUA’s for Remdesivir and mRNA vaccines.” Anthony Fauci said that Remdesivir cleared viruses in 11 days instead of 15 days, never mind how many people died. They said hydroxychloroquine didn’t work, even though people weren’t dying. After Remdesivir was authorized by the FDA, it became a “standard of care” in numerous clinical trials. Just about anything is better than Remdesivir, so whatever Pharma and the Philanthropists wanted to use looked good compared to Remdesivir.
As Steve Kirsch said on Twitter on May 10, 2020: “Peginterferon lambda is 100x better than remdesivir.”
Mr. Kirsch also reported on Twitter that he had a friend at Gilead, the patent holder of Remdesivir.
The Biodefense establishment got paid for their Remdesivir poison that they had unsuccessfully tried to get approved for over a decade. Pharma and the Globalists approved synthetic mRNA that modified the human genome, made hundreds of billions of dollars, and advanced their Globalist agendas in numbers of other ways. The worst part of the reported coronavirus- the spike protein - was exactly what was in the vaccines.
I invite Steve Kirsch to use his statistical acumen and those hundreds of millions of Disney dollars to help us figure it all out. Just for starters, why don’t you compare death rates from Hydroxychloroquine and Remdesivir in government-funded clinical trials? Just to see what it looks like, you know?